Skip to main content
. Author manuscript; available in PMC: 2014 Feb 6.
Published in final edited form as: Antivir Ther. 2011;16(7):1063–1072. doi: 10.3851/IMP1874

Figure 2.

Figure 2

Mean percentage change in C-telopeptide (CTX) and osteocalcin in tenofovir (TDF)-and non-TDF groups 6–12 months after initiation of antiretroviral therapy. P< 0.001 for all changes from baseline. Error bars represent standard errors. P values represent difference between TDF and non-TDF groups.